Mymetics Corp (MYMX)

[Work Harder]

Jean-Paul Prieels joined GlaxoSmithKline Biologicals in 1987 as Associate Director R&D Projects Evaluation. His responsibilities gradually expanded to lead the global vaccine R&D development activities in Rixensart, Belgium.

Pevion has in-house development capability and expertise, including a state-of-the-art and industrially scalable GMP manufacturing process. Located near Bern, Pevion was established by its founding fathers, Bachem AG (SWX: BANB) and Berna Biotech (now Crucell, a Johnson & Johnson subsidiary). To date, Pevion has raised a total of CHF 45 million to date from its founders and investors, BZ Bank, CCP and BB Biotech Ventures.

https://www.asx.com.au/asxpdf/20090309/pdf/31gh5dqy4v7c74.pdf

https://www.sec.gov/Archives/edgar/data/927761/000095015209002330/l35768aexv99w1.htm